FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955757379> ?p ?o ?g. }

• W2955757379 endingPage "75" @default.
• W2955757379 startingPage "75" @default.
• W2955757379 abstract "75 Objectives: 177Lutetium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (177Lu-DOTMP) is a new bone seeking therapeutic radiotracer. Objectives of this study were to evaluate the efficacy of 177Lu-DOTMP (a) in reducing bone pain, (b) in improving the quality of life (QOL) and (c) to study the toxicity profile in patients with biopsy proven carcinoma with skeletal metastasis. Methods: Ongoing prospective interventional study being conducted since July 2017. Patients (≥18 years) with painful skeletal metastases from prostate, breast, lung and nasopharyngeal carcinoma documented on 99mTc-MDP bone scan were administered with single dose (37 MBq /kg) of 177Lu-DOTMP intravenously. Post therapy whole body images were acquired after 24 hours to confirm distribution of 177Lu-DOTMP at the skeletal metastatic sites. Response was assessed by analysing visual analogue score (VAS), analgesic score (AS) and Eastern Cooperative Oncology Group (ECOG) score at baseline and 1, 2, 4, 8, 12 weeks post therapy. Response was graded as- significant: >50% reduction in post therapy VAS compared to baseline; partial response: 10-50% reduction in VAS and no response : 0-10% VAS reduction. Toxicity was assessed and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5). Results: Eighteen patients (13 males, 5 females) with mean age 56 years were recruited in the study. Overall response was seen in 14 patients (78%) which was significant in 10 patients. Partial response was seen in 4 patients whereas 4 had not response to therapy. In responders, pain relief started at a median duration of 7 days (range 4-20 days) post therapy, with the maximum pain relief at 8 weeks. Statistically significant reduction in mean VAS was noted, from 7.9 at baseline to 3.9 at 4 weeks and 2.5 at 8 weeks post therapy (p<0.001). Mean AS reduced to 2.5 and 1.6 at 4 and 8 weeks post therapy from 3.8 at baseline (p<0.001). Improvement in QOL was noted in nine (50%) patients as evidenced by improvement in the mean ECOG score from 3.0 at baseline to 2.6 at 1month post therapy (p=0.02). Among the subset of the patients treated, best response rate was seen in breast carcinoma patients (100%) and least response rate in lung carcinoma patients (40%). Grade II/III anemia and thrombocytopenia were the only notable adverse events noted after therapy with spontaneous recovery within next 4 weeks in all patients except two in whom blood transfusion was given. Anemia was noted in nine patients with median nadir at 4 weeks (range 2-12 weeks) whereas thrombocytopenia was noted in four patients with median nadir at 3 weeks (range 1-4 weeks). Conclusions: 177Lu-DOTMP is proven to be safe and effective therapeutic radiotracer in reducing metastatic bone pain along with significant improvement in quality of life of breast, prostate and nasopharyngeal carcinoma patients." @default.
• W2955757379 created "2019-07-12" @default.
• W2955757379 creator A5009998252 @default.
• W2955757379 creator A5040007918 @default.
• W2955757379 creator A5053724034 @default.
• W2955757379 creator A5064391849 @default.
• W2955757379 creator A5069645910 @default.
• W2955757379 date "2019-05-01" @default.
• W2955757379 modified "2023-09-23" @default.
• W2955757379 title "Evaluation of the efficacy and safety of 177Lu-DOTMP in metastatic bone pain palliation" @default.
• W2955757379 hasPublicationYear "2019" @default.
• W2955757379 type Work @default.
• W2955757379 sameAs 2955757379 @default.
• W2955757379 citedByCount "0" @default.
• W2955757379 crossrefType "journal-article" @default.
• W2955757379 hasAuthorship W2955757379A5009998252 @default.
• W2955757379 hasAuthorship W2955757379A5040007918 @default.
• W2955757379 hasAuthorship W2955757379A5053724034 @default.
• W2955757379 hasAuthorship W2955757379A5064391849 @default.
• W2955757379 hasAuthorship W2955757379A5069645910 @default.
• W2955757379 hasConcept C121608353 @default.
• W2955757379 hasConcept C126322002 @default.
• W2955757379 hasConcept C141071460 @default.
• W2955757379 hasConcept C14184104 @default.
• W2955757379 hasConcept C188816634 @default.
• W2955757379 hasConcept C197934379 @default.
• W2955757379 hasConcept C2776139714 @default.
• W2955757379 hasConcept C2776694085 @default.
• W2955757379 hasConcept C2777783956 @default.
• W2955757379 hasConcept C2777793932 @default.
• W2955757379 hasConcept C2778822529 @default.
• W2955757379 hasConcept C2779984678 @default.
• W2955757379 hasConcept C2780192828 @default.
• W2955757379 hasConcept C29730261 @default.
• W2955757379 hasConcept C71924100 @default.
• W2955757379 hasConceptScore W2955757379C121608353 @default.
• W2955757379 hasConceptScore W2955757379C126322002 @default.
• W2955757379 hasConceptScore W2955757379C141071460 @default.
• W2955757379 hasConceptScore W2955757379C14184104 @default.
• W2955757379 hasConceptScore W2955757379C188816634 @default.
• W2955757379 hasConceptScore W2955757379C197934379 @default.
• W2955757379 hasConceptScore W2955757379C2776139714 @default.
• W2955757379 hasConceptScore W2955757379C2776694085 @default.
• W2955757379 hasConceptScore W2955757379C2777783956 @default.
• W2955757379 hasConceptScore W2955757379C2777793932 @default.
• W2955757379 hasConceptScore W2955757379C2778822529 @default.
• W2955757379 hasConceptScore W2955757379C2779984678 @default.
• W2955757379 hasConceptScore W2955757379C2780192828 @default.
• W2955757379 hasConceptScore W2955757379C29730261 @default.
• W2955757379 hasConceptScore W2955757379C71924100 @default.
• W2955757379 hasLocation W29557573791 @default.
• W2955757379 hasOpenAccess W2955757379 @default.
• W2955757379 hasPrimaryLocation W29557573791 @default.
• W2955757379 hasRelatedWork W114937152 @default.
• W2955757379 hasRelatedWork W1935659346 @default.
• W2955757379 hasRelatedWork W1989098069 @default.
• W2955757379 hasRelatedWork W2032489540 @default.
• W2955757379 hasRelatedWork W2042944854 @default.
• W2955757379 hasRelatedWork W2047873387 @default.
• W2955757379 hasRelatedWork W2136505615 @default.
• W2955757379 hasRelatedWork W2171817128 @default.
• W2955757379 hasRelatedWork W2301475579 @default.
• W2955757379 hasRelatedWork W2365350341 @default.
• W2955757379 hasRelatedWork W2405691589 @default.
• W2955757379 hasRelatedWork W2464238853 @default.
• W2955757379 hasRelatedWork W2592796088 @default.
• W2955757379 hasRelatedWork W2891466495 @default.
• W2955757379 hasRelatedWork W2892787700 @default.
• W2955757379 hasRelatedWork W3029280388 @default.
• W2955757379 hasRelatedWork W3207802157 @default.
• W2955757379 hasRelatedWork W56313902 @default.
• W2955757379 hasRelatedWork W96067564 @default.
• W2955757379 hasRelatedWork W2172768768 @default.
• W2955757379 hasVolume "60" @default.
• W2955757379 isParatext "false" @default.
• W2955757379 isRetracted "false" @default.
• W2955757379 magId "2955757379" @default.
• W2955757379 workType "article" @default.